CA125 and UQCRFS1 FISH studies of ovarian carcinoma

Gynecologic Oncology

Volumn 90, Issue 1, 2003, Pages 29-36

  Kaneko, Saori J ^a,b   Gerasimova, Tsilya ^a   Smith, S Terrell ^c   Lloyd, Kenneth O ^d   Suzumori, Kaoru ^b   Young, S Robert ^a,e  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c South Carolina Cancer Center   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Two Medical Park ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; IRON SULFUR PROTEIN; PARAFFIN; RIESKE IRON-SULFUR PROTEIN; UBIQUINOL CYTOCHROME C REDUCTASE;

ADULT; AGED; ARTICLE; ASCITES; BACTERIAL ARTIFICIAL CHROMOSOME; BLOOD ANALYSIS; CALCULATION; CANCER CELL CULTURE; CANCER PATIENT; CENTROMERE; CHROMOSOME 19P; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; METAPHASE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; OUTCOMES RESEARCH; OVARY CARCINOMA; PRIORITY JOURNAL; BLOOD; CELL CULTURE; CHROMOSOME 19; CHROMOSOME MAP; GENE DOSAGE; GENETICS; OVARY TUMOR;

CA-125 ANTIGEN; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 19; ELECTRON TRANSPORT COMPLEX III; FEMALE; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; IRON-SULFUR PROTEINS; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; TUMOR CELLS, CULTURED;

EID: 0037486956     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00144-6     Document Type: Article

References (28)

1. Bast R.C. Jr, Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 68:1981;1331-1337.
2. Bast R.C. Jr, Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H., Leavitt T., Griffiths C.T., Parker L., Zurawski V.R. Jr, Knapp R.C., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309:1983;883-887.
3. Bast R.C. Jr, Xu F.J., Yu Y.H., Barnhill S., Zhang Z., Mills G.B. CA125 the past and the future . Int J Biol Markers. 13:1998;179-187.
4. Yin B.W.T., Lloyd K.O. Molecular cloning of the CA125 ovarian cancer antigen. J Biol Chem. 276:2001;27371-27375.
5. Lloyd K.O., Yin B.W.T., Kudryashov V. Isolation and characterization of ovarian cancer antigen CA125 using a new monoclonal antibody (VK-8) identification as a mucin-type molecule . Int J Cancer. 71:1997;842-850.
6. O'Brien T.J., Beard J.B., Underwood L.J., Dennis R.A., Santin A.D., York L. The CA125 gene an extracellular superstructure dominated by repeat sequences . Tumor Biol. 22:2001;348-366.
7. Hovig E., Rye P.D., Warren D.J., Nustad K. CA125 the end of the beginning . Tumor Biol. 22:2001;345-347.
8. Yin B.W.T., Dnistrian A., Lloyd K.O. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 98:2002;737-740.
9. O'Brien T.J., Beard J.B., Underwood L.J., Shigemasa K. The CA125 gene a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure . Tumor Biol. 23:2002;154-169.
10. Pandis N., Heim S., Bardi G., Limon J., Mandahl N., Mitelman F. Improved technique for short-term culture and cytogenetic analysis of human breast cancer. Genes Chrom Cancer. 5:1992;14-20.
11. Morrison LE, Legator M. Multicolor fluorescence in situ hybridization techniques. In: Andreeff D, Pinkel D, editors. Introduction to fluorescence in situ hybridization: principles and clinical applications. Wiley-Liss, Inc., 1999, p. 3-12.
12. Sano T., Hikino T., Niwa T., Kashiwabara K., Oyama T., Fukuda T., Nakajima T. In situ hybridization with biotinylated tyramide amplification detection of human papillomavirus DNA in cervical neoplastic lesions . Modern Pathol. 11:1998;19-23.
13. Morrison L.E., Legator M. Multicolor fluorescence in situ hybridization techniques. Andreeff M., Dinhel D. Introduction to fluorescence in situ hybridization principles and clinical applications . 1999;77-118 Wiley-Liss, New York.
14. Tholander B., Lindgren A., Taube A., Stenson S. Immunohistochemical detection of CA-125 and carcinoembryonic antigen in ovarian tumors in relation to corresponding preoperative serum levels. Int J Gynecol Cancer. 2:1992;263-270.
15. Halila H., Stenman U.H., Seppala M. Ovarian cancer antigen CA125 levels in pelvic inflammatory disease and pregnancy. Cancer. 57:1986;1327-1329.
16. Sjövall K., Nilsson B., Einhorn N. The significance of serum CA125 elevation in malignant and nonmalignant diseases. Gynecol Oncol. 85:2002;175-178. (doi:10.1006/gyno.2002.6603).
17. Norum L.F., Erikstein B., Nustad K. Elevated CA125 in breast cancer - a sign of advanced disease. Tumor Biol. 22:2001;223-228.
18. Topalak O., Saygili U., Soyturk M., Karaca N., Batur Y., Uslu T., et al. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases a comparative study . Gynecol Oncol. 85:2002;108-113. (doi: 10.1006/gyno.2001.6575).
19. Bergmann J.F., Bidart J.M., George M., Beaugrand M., Levy V.G., Bohuon C. Elevation of CA 125 in patients with benign and malignant ascites. Cancer. 59:1987;213-217.
20. Neunteufel W., Breitenecker G. Tissue expression of CA 125 in benign and malignant lesions of ovarian and fallopian tube a comparison with CA 19-9 and CEA . Gynecol Oncol. 32:1989;297-302.
21. Zeimet A.G., Marth C., Offner F.A., Obrist P., Uhl-Steidl M., Feichtinger H., et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 62:1996;384-389.
22. Sait S.N.J., Qadir M.U., Conroy J.M., Matsui S., Nowak N.J., Baer M.R. Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndrome identification of new amplification regions by fluorescence in situ hybridization and spectral karyotyping . Genes Chrom Cancer. 34:2002;42-47.
23. Voet D., Voet J.G., Pratt C.W. Fundamentals of biochemistry - upgrade edition. 2001;492-528 Wiley, New York.
24. Thompson F.H., Liu Y., Emerson J., Weinstein R., Makar R., Trent J.M., et al. Simple numeric abnormalities as primary karyotype changes in ovarian carcinoma. Genes Chrom Cancer. 10:1994;262-266.
25. Thompson F.H., Nelson M.A., Trent J.M., Guan X.Y., Liu Y., Yang J.M., et al. Amplification of 19q13.1-q13.2 sequences in ovarian cancer. Cancer Genet Cytogenet. 87:1996;55-62.
26. Kauraniemi P., Bärlund M., Monni O., Kallioniemi A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA Microarrays. Cancer Res. 61:2001;8235-8240.
27. Shishi J., Ghazizadeh M., Oguro T., Aihara K., Araki T. Immunohistochemical localization of CA125 antigen in formalin-fixed paraffin sections of ovarian tumors with the use of pronase. Am J Clin Pathol. 85:1986;595-598.
28. Kabawat S.E., Bast R.C., Welch W.R., Knapp R.C., Colvin R.B. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol. 79:1983;98-104.